• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca, Max Planck Institute to create satellite chemistry unit

AstraZeneca, Max Planck Institute to create satellite chemistry unit

July 9, 2014
CenterWatch Staff

The Max Planck Institute of Molecular Physiology (MPI), Germany, will establish a satellite unit in cardiovascular and metabolic disease (CVMD) with AstraZeneca's CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.

The new collaboration will see AZ scientists working side-by-side with researchers from the Max Planck Institute of Molecular Physiology, in the department of Chemical Biology, led by Professor Herbert Waldmann. The satellite unit will focus on novel chemistry and chemical biology in areas of new modality chemistry such as stabilised peptides, macrocycles and conjugation chemistry.

Professor Herbert Waldmann, director of the department of Chemical Biology, MPI Dortmund, said, "This novel concept for a strategic alliance between a pharmaceutical company and a biomedical institute like the Max Planck Institute of Molecular Physiology promises to break new ground for drug discovery.”

Cardiovascular and metabolic diseases represent one of AZ's three core therapeutic areas, with the aim of developing innovative treatments that address the underlying biology to stop, reverse or cure diseases with high unmet medical need. The collaboration with the Max Planck Institute will support identification of new targets in the company's three areas of research focus in CVMD: cardiac regeneration, islet health (diabetes) and diabetic nephropathy.

In March 2013, AZ initiated a similar collaboration with the Swedish medical university Karolinska Institutet that created an Integrated Translational Research Center (ICMC) for cardiovascular and metabolic disease and regenerative medicine located at Karolinska Institutet's site in Stockholm. The ICMC conducts preclinical and clinical studies aimed at advancing the understanding of cardiovascular and metabolic disease pathophysiology and assessing new drug targets for AZ's two biotech units, the iMed and MedImmune. 

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing